The estimated Net Worth of Elazar Rabbani is at least $3.33 Milion dollars as of 14 January 2019. Elazar Rabbani owns over 2,782 units of Enzo Biochem stock worth over $1,843,713 and over the last 21 years he sold ENZ stock worth over $0. In addition, he makes $1,487,800 as Chairman of the Board, Chief Executive Officer a Secretary at Enzo Biochem.
Sign up
Elazar Rabbani ENZ stock SEC Form 4 insiders trading
Elazar has made over 5 trades of the Enzo Biochem stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 2,782 units of ENZ stock worth $7,511 on 14 January 2019.
The largest trade he's ever made was exercising 159,091 units of Enzo Biochem stock on 25 October 2017 worth over $477,273. On average, Elazar trades about 8,228 units every 93 days since 2004. As of 14 January 2019 he still owns at least 1,661,003 units of Enzo Biochem stock.
You can see the complete history of Elazar Rabbani stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Elazar Rabbani biography
Dr. Elazar Rabbani Ph.D. serves as Chairman of the Board, Chief Executive Officer, Secretary of the Company. The Company believes that having one person, particularly Dr. Rabbani with his deep industry and executive management experience, his extensive knowledge of the operations of the Company and his own history of innovation and strategic thinking, to serve as both Chief Executive Officer and Chairman of the Board is the best leadership structure for the Company. The Board believes this demonstrates to employees, customers and shareholders that the Company has a cohesive and coordinated leadership, with a single clear approach to managing the Company’s operations. This unity of leadership promotes strategy development and execution, timely decision-making and effective management of Company resources. The Company believes that it has been well served by this structure.
What is the salary of Elazar Rabbani?
As the Chairman of the Board, Chief Executive Officer a Secretary of Enzo Biochem, the total compensation of Elazar Rabbani at Enzo Biochem is $1,487,800. There are no executives at Enzo Biochem getting paid more.
How old is Elazar Rabbani?
Elazar Rabbani is 77, he's been the Chairman of the Board, Chief Executive Officer a Secretary of Enzo Biochem since 2009. There are 1 older and 13 younger executives at Enzo Biochem. The oldest executive at Enzo Biochem, Inc. is Dr. Elazar Rabbani Ph.D., 78, who is the Co-Founder, Chairman, Chief Scientific Officer & Sec..
What's Elazar Rabbani's mailing address?
Elazar's mailing address filed with the SEC is C/O ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK, NY, 10022.
Insiders trading at Enzo Biochem
Over the last 22 years, insiders at Enzo Biochem have traded over $2,615,763 worth of Enzo Biochem stock and bought 1,070,494 units worth $3,103,461 . The most active insiders traders include Bradley Louis Radoff, Management Corp Harbert Dis... a Elazar Rabbani. On average, Enzo Biochem executives and independent directors trade stock every 127 days with the average trade being worth of $59,099. The most recent stock trade was executed by Kara Cannon on 21 February 2024, trading 10,640 units of ENZ stock currently worth $11,810.
What does Enzo Biochem do?
enzo biochem inc is a financial services company located in 60 executive blvd, farmingdale, new york, united states.
What does Enzo Biochem's logo look like?
Complete history of Elazar Rabbani stock trades at Enzo Biochem
Enzo Biochem executives and stock owners
Enzo Biochem executives and other stock owners filed with the SEC include:
-
Elazar Rabbani,
Chairman of the Board, Chief Executive Officer, Secretary -
Barry Weiner,
President, Treasurer -
Dr. Elazar Rabbani Ph.D.,
Co-Founder, Chairman, Chief Scientific Officer & Sec. -
Barry W. Weiner,
Founder, Treasurer & Pres -
Dieter Schapfel,
Chief Medical Director - Enzo Clinical Labs -
Kara Cannon,
Chief Commercial Officer -
Dr. Dieter Schapfel M.D.,
Chief Medical Director of Enzo Clinical Labs -
David Bench,
Chief Financial Officer, Principal Accounting Officer -
David A. Bench,
CFO & Principal Accounting Officer -
Dov Perlysky,
Lead Independent Director -
Rebecca Fischer,
Independent Director -
Ian Walters,
Independent Director -
Mary Tagliaferri,
Independent Director -
Kara Cannon,
Chief Commercial Officer -
Hamid Erfanian,
CEO & Director -
Bruce A. Dey,
VP of Sales & Marketing - Enzo Clinical Labs -
Gregory M. Bortz,
Director -
Bernard L Kasten,
Director -
David C Goldberg,
VP CorpDev Pres Enz Clin Labs -
Steven J Pully,
Director -
Bruce A. Hanna,
Director -
James Michael O'brien,
EVP of Finance -
Peter J Iv Clemens,
10% owner -
Management Corp Harbert Dis...,
-
Stanford S Warshawsky,
Director -
Fabian Blank,
Director -
Christine Fischette,
Pres., Enzo Therapeutics, Inc. -
Irwin Gerson,
Director -
John Delucca,
Director -
Stephen B H Kent,
Director -
Dean Engelhardt,
Executive Vice President -
Melvin F Lazar,
Director -
Barbara E Thalenfeld,
VP Corporate Development -
John B Sias,
Director -
Carl W Balezentis,
Pres., Enzo Life Sciences -
Kevin Krenitsky,
President, Enzo Clinical Labs -
Shahram K Rabbani,
COO, Treasurer & Secretary -
Norman E Kelker,
Senior Vice President -
Herbert B Bass,
VP of Finance -
Andrew P Whiteley,
VP BusDev-COO Enzo Lif Sci Inc -
Bradley Louis Radoff,
Director -
James G. Wolf,
-
Hamid Erfanian,
Chief Executive Officer -
Patricia Eckert,
Chief Financial Officer